Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue$85.47M$85.47M−5.5% vs Q1 2018 Net Income$18.34M$18.34M−30.4% vs Q1 2018 EPS Diluted$0.34$0.34−30.6% vs Q1 2018 Operating Income$25,428,000−19.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$32,772,000+21.9% Margins · derivedOperating margin29.7%−5.0 pt vs Q1 2018
Net margin21.5%−7.7 pt vs Q1 2018
ended Mar 31, 2019 · filed May 10, 2019 · 40 d after period end